#United States #New York #Class Action #Gross Law Firm #Capricor Therapeutics

Capricor Therapeutics Class Action Alert

In a recent announcement from The Gross Law Firm, shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) are being urged to come forward if they purchased shares within a specified timeframe and have sustained losses. This call to action is particularly relevant for individuals who may wish to assume the role of lead plaintiff in a class action lawsuit connected to alleged securities violations.

Context of the Lawsuit

The class action period has been outlined as spanning from December 17, 2025, to July 29, 2026. Allegations in the case assert that Capricor Therapeutics misrepresented or failed to disclose crucial information during this timeframe, which might have influenced shareholders' decisions. Specifically, the complaint alleges that the company altered its previously outlined statistical analysis plan without obtaining prior agreement from the FDA. This change raised significant questions regarding the validity of clinical data for its key product candidate, Deramiocel, intended for treating Duchenne muscular dystrophy.

Core Allegations Include:

1. Materially misleading statements made by the company regarding their processes and a lack of disclosure about modifications to clinical trial protocols.
2. Risks associated with the approval of Deramiocel, given that the FDA had not acknowledged the changes to the analysis plan prior to resubmission.
3. That these actions led to a distortion of the company's actual business prospects and operations in the eyes of investors.

The legal implications of these allegations are serious, as they suggest a breach of fiduciary duty and mismanagement that could ultimately lead to investor losses. The legal team at Gross Law Firm is prepared to assist shareholders in navigating the complexities of this case and ensuring that their collective voice is heard.

Deadline for Shareholders

Prospective participants have until September 28, 2026, to register their claims and potentially join as lead plaintiffs in the ongoing lawsuit. The Gross Law Firm emphasizes that interested individuals should not delay in registering, as time is of the essence in such legal matters. By registering, shareholders will gain access to monitoring software that will keep them updated on the case's progress throughout its duration.

Participating in the Class Action

For shareholders interested in participating in this class action, the process begins with the completion of a registration form on the Gross Law Firm’s website. This step is critical to ensure proper representation and support throughout the legal proceedings. The firm assures that there is no upfront cost or obligation associated with joining the class action.

Why Choose The Gross Law Firm?

The Gross Law Firm has a national reputation for representing investors in class action lawsuits. Their commitment to protecting the rights of investors who have suffered losses from false or misleading company statements underscores their mission. With an experienced team dedicated to fighting for shareholder interests, the firm aims to restore investor confidence and ensure that companies uphold ethical business practices.

Contact Information

For shareholders who believe they may be affected by these developments, The Gross Law Firm encourages immediate outreach. Contact details are available for investors who wish to learn more about their rights or participating in the class action:

• - Phone: (646) 453-8903
• - Email: [email protected]
• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018

In conclusion, shareholders of Capricor Therapeutics who have incurred losses due to alleged misrepresentations have a vital opportunity to join a collective legal effort. By acting quickly, they can seek the restitution they deserve while also holding the company accountable for its actions.